Gastrointestinal Cancer | Specialty

An Update on Molecular Testing in Colorectal Cancer

July 12th 2016

Dr. Overman on Implications of Tumor Location Data for Patients With mCRC

July 11th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

July 9th 2016

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC

July 8th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

Dr. Daniele on Impact of Regorafenib in HCC

July 8th 2016

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

First-Line Cetuximab Combo Validated in RAS Wild-Type Colorectal Cancer

July 3rd 2016

The addition of cetuximab to standard FOLFOX-4 chemotherapy in the first-line treatment of patients with RAS wild-type metastatic colorectal cancer significantly improved survival outcomes.

MABp1 Improves Symptoms in Phase III CRC Study

July 3rd 2016

MABp1, a novel anti–interleukin 1-alpha antibody, was safe, well-tolerated, and demonstrated a significant impact on symptoms compared with placebo for patients with advanced colorectal cancer.

Nivolumab Spurs Encouraging Responses in Metastatic Anal Cancer

July 2nd 2016

The first prospective study to investigate the use of immunotherapy in patients with squamous cell carcinoma of the anal canal demonstrated promising results following treatment with nivolumab.

FGFR Inhibitor ARQ-087 Safe, Effective in Early Cholangiocarcinoma Study

July 1st 2016

Treatment with ARQ-087 demonstrated promising signs of clinical activity with a manageable safety profile for patients with FGFR2 fusion-positive advanced and/or metastatic intrahepatic cholangiocarcinoma.

SIRT Improves Depth of Response in mCRC Patients With Liver Mets

July 1st 2016

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.

Adding IMAB362 to Chemo Extends Survival in Advanced Gastric Cancer

July 1st 2016

IMAB362, a novel chimeric IgG1 backbone antibody highly specific for CLDN18.2, extended median overall survival by 4.8 months when added to standard chemotherapy in patients with advanced gastric cancer.

Dr. Navesh K. Sharma on Older Patients Tolerating Internal Radiation

July 1st 2016

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses that age should not be a deciding factor in giving internal radiation to patients with liver cancer.

Dr. Jordi Bruix on the Impact Regorafenib Will Have on Liver Cancer Treatment

July 1st 2016

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).

Dr. Adam Bass on the Origins of Different Gastric Tumor Types

July 1st 2016

Dr. Adam Bass, MD, Dana-Farber Cancer Institute, discusses the causes for different types of gastric cancer.

Dr. Berger on the Significance of the Cologuard Screening Test

July 1st 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses the significance and benefits of the Cologuard screening test for colorectal cancer.

Dr. Yurgelun on Susceptibility Gene Mutations in CRC

June 30th 2016

Dr. Eileen O'Reilly on Factors to Consider in Pancreatic Cancer Treatment

June 30th 2016

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.

Daniel Sargent on International Collaboration for Colon Cancer Research

June 30th 2016

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

QOL Sustained When Adding MM-398 to Standard Care in Pancreatic Cancer

June 30th 2016

Adding MM-398 (irinotecan liposome injection; nal-IRI; Onivyde) to 5-fluorouracil and leucovorin had no negative effect on quality of life while significantly improving overall survival in patients with metastatic pancreatic cancer.

Dr. John Marshall on Differentiating Squamous and Adenocarcinoma in GI Cancers

June 30th 2016

John L. Marshall, MD, chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, clinical research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the difference between squamous and adenocarcinoma in esophageal and gastric cancer.